![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC38A11 |
Gene summary for SLC38A11 |
![]() |
Gene information | Species | Human | Gene symbol | SLC38A11 | Gene ID | 151258 |
Gene name | solute carrier family 38 member 11 | |
Gene Alias | AVT2 | |
Cytomap | 2q24.3 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q08AI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
151258 | SLC38A11 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.96e-35 | 7.12e-01 | 0.3005 |
151258 | SLC38A11 | CRC-1-8810 | Human | Colorectum | CRC | 1.40e-59 | 1.18e+00 | 0.6257 |
151258 | SLC38A11 | HCC1_Meng | Human | Liver | HCC | 1.68e-03 | -1.05e-01 | 0.0246 |
151258 | SLC38A11 | HCC2 | Human | Liver | HCC | 9.53e-11 | 1.23e-01 | 0.5341 |
151258 | SLC38A11 | S014 | Human | Liver | HCC | 6.29e-04 | 5.45e-01 | 0.2254 |
151258 | SLC38A11 | S016 | Human | Liver | HCC | 5.14e-12 | 6.80e-01 | 0.2243 |
151258 | SLC38A11 | HTA12-23-1 | Human | Pancreas | PDAC | 8.00e-12 | 8.81e-01 | 0.3405 |
151258 | SLC38A11 | HTA12-25-1 | Human | Pancreas | PDAC | 3.52e-06 | 5.06e-01 | 0.313 |
151258 | SLC38A11 | HTA12-26-1 | Human | Pancreas | PDAC | 4.88e-07 | 4.28e-01 | 0.3728 |
151258 | SLC38A11 | HTA12-29-1 | Human | Pancreas | PDAC | 6.38e-18 | 5.05e-01 | 0.3722 |
151258 | SLC38A11 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 8.99e-01 | 0.3624 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC38A11 | SNV | Missense_Mutation | novel | c.181N>G | p.Leu61Val | p.L61V | Q08AI6 | protein_coding | tolerated(0.2) | benign(0.093) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | c.415N>A | p.Val139Ile | p.V139I | Q08AI6 | protein_coding | tolerated(0.47) | benign(0.044) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.137N>A | p.Thr46Asn | p.T46N | Q08AI6 | protein_coding | deleterious(0.01) | possibly_damaging(0.77) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
SLC38A11 | SNV | Missense_Mutation | c.662C>G | p.Thr221Arg | p.T221R | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.1061N>A | p.Val354Asp | p.V354D | Q08AI6 | protein_coding | deleterious(0.01) | possibly_damaging(0.739) | TCGA-OL-A5D7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
SLC38A11 | insertion | In_Frame_Ins | novel | c.282_283insGTCAAAGATCAGATAGTTGTAGCTGTGCAG | p.Phe94_Ile95insValLysAspGlnIleValValAlaValGln | p.F94_I95insVKDQIVVAVQ | Q08AI6 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SLC38A11 | SNV | Missense_Mutation | rs368927720 | c.493N>G | p.Ile165Val | p.I165V | Q08AI6 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | novel | c.506N>T | p.Gly169Val | p.G169V | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SLC38A11 | SNV | Missense_Mutation | c.1208N>A | p.Ser403Asn | p.S403N | Q08AI6 | protein_coding | deleterious_low_confidence(0) | benign(0.09) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC38A11 | SNV | Missense_Mutation | rs754460440 | c.1072N>A | p.Val358Ile | p.V358I | Q08AI6 | protein_coding | tolerated(0.71) | benign(0.009) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |